^
    3ms
    Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer. (PubMed, Clin Cancer Res)
    AZD6422 was safe and efficacious in patient-derived, CLDN18.2-positive murine models of gastrointestinal cancers. Our data support further clinical development of AZD6422 for patients with these cancers.
    Preclinical • Journal • CAR T-Cell Therapy
    |
    CLDN18 (Claudin 18) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    CLDN18.2 positive
    |
    AZD6422
    12ms
    Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, Peking University | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    AZD6422
    1year
    Preclinical evaluation and anti-tumor activity of AZD6422, a CLDN18.2 targeting armored CAR-T for gastric, esophageal and pancreatic cancers (SITC 2023)
    2 and TGFβ levels as determined by IHC. Conclusions Taken together, the selection of CAR-T design which provided therapeutic margin in relevant murine models, addition of armoring and optimization of manufacturing enabled generation of a lead molecule which provides efficacy in relevant cell line and patient derived xenograft models of gastric, pancreatic and esophageal cancers and supports further clinical development of AZD6422.
    Preclinical • IO biomarker
    |
    CLDN18 (Claudin 18) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    AZD6422
    over1year
    Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors (clinicaltrials.gov)
    P1, N=96, Not yet recruiting, Peking University
    New P1 trial • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    AZD6422